Sarah Smith

Sarah Smith

Expertise: ESG Investing, Electric Vehicle Stocks, Short Squeeze Stocks

Education: BA, Government and Gender, Sexuality and Women’s Studies, The College of William & Mary

Awards & Accomplishments: Top 5% of stock pickers on TipRanks

About Sarah:
Sarah Smith is an experienced editor and writer who works to help retail investors make sense of what’s happening every day on Wall Street, and she’s particularly interested in ESG investing, EV stocks, and the rise of speculative trading activity like short squeezes. She has also written for Kiplinger.com, Smithsonian, and Washington City Paper. Sarah is currently working to become a Chartered Financial Analyst (CFA) and has already earned bachelor’s degrees in Government and Gender, Sexuality and Women’s Studies from the College of William and Mary. Her work for InvestorPlace.com focuses on helping investors understand the causes and impacts of daily stock and crypto market movements, and how a disruption in who invests – and how they invest – transforms the market. Sarah is recognized among the top 5% of stock pickers on TipRanks and has an average return of 50%. She lives in Arlington, Virginia.

Connect with Sarah on LinkedIn.

Recent Articles

GoodRx IPO: 6 Things for Potential GDRX Investors to Know

Healthcare bulls should be excited about the GoodRx IPO. Here is everything you need to know about the prescription drug comparison platform.

VXRT Stock: Vaxart Shoots Higher on Human Trial Approval

Vaxart just announced it will begin enrolling participants in human trials of its coronavirus vaccine. VXRT stock is popping in response.

The Ultimate EV Investing Guide: 23 Electric Car Stocks to Watch

This all-encompassing guide to electric car stocks will teach you everything you need to know to profit from the booming market trend.

Nvidia Stock Rallies Monday on Arm Holdings Acquisition

Nvidia stock is rallying Monday morning on news it secured a deal with SoftBank to buy Arm Holdings for $40 billion. Here's what it means.

Pfizer Stock Pops on Vaccine Timeline News, Trial Expansion

Pfizer stock and partner BioNTech are rallying Monday morning on news the two companies could vaccinate Americans before the end of 2020.